ArticleNature medicine2017
The activated conformation of integrin β
Registry-linked trialAbstract read
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03778346 (Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells), which is not on this map. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
Who cites it
100 citing papers in PubMed, 142 citations in OpenAlex.
- Discovery of candidate antibodies and antigens for acute myeloid leukemia therapy by combining whole-cell phage display selection and CRISPR-Cas9 library screening.Antibody therapeutics · 2026Article
- Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets.bioRxiv : the preprint server for biology · 2026Article
- A bortezomib resistance-related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma.Discover oncology · 2026Article
- CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies.Internal medicine (Tokyo, Japan) · 2026Review
- Integrin α6 Targeted Tumor Theranostics.Phenomics (Cham, Switzerland) · 2025Review
- Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.Genome medicine · 2025Article
- Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.Biomarker research · 2025Review
- Targets for CAR Therapy in Multiple Myeloma.International journal of molecular sciences · 2025Review
- Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.Cancers · 2025Review
- CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant.Nature cancer · 2025Article
- Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma.Cancer immunology, immunotherapy : CII · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy.Frontiers in immunology · 2025Review
- CAR-NK cells derived from cord blood originate mainly from CD56Molecular therapy. Methods & clinical development · 2024Article
- Review
- Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.Experimental hematology & oncology · 2024Review
- Updates on CAR T cell therapy in multiple myeloma.Biomarker research · 2024Review
- A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts.Cancer immunology, immunotherapy : CII · 2024Article
- T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Beyond BCMA: newer immune targets in myeloma.Blood advances · 2024Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 9 institutions in 1 country.
Naoki HosenDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID http://orcid.org/0000-0001-9570-0947
Yukiko MatsunagaLaboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan.
Kana HasegawaDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroshi MatsunoDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Yuki NakamuraDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Mio MakitaDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kouki WatanabeDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Mikako YoshidaDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kei SatohDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Soyoko MorimotoDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Fumihiro FujikiDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroko NakajimaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Jun NakataDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Sumiyuki NishidaDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Akihiro TsuboiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoshihiro OkaDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Masahiro ManabeDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Hiroyoshi IchiharaDepartment of Hematology, Fuchu Hospital, Osaka, Japan.
Yasutaka AoyamaDepartment of Hematology, Fuchu Hospital, Osaka, Japan.
Atsuko MugitaniDepartment of Hematology, Fuchu Hospital, Osaka, Japan.
Takafumi NakaoDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Masayuki HinoDepartment of Hematology and Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Ryosuke UchiboriDivision of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan.
Keiya OzawaDivision of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan.
Yoshihiro BabaDivision of Immunology and Genome Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1194-8046
Naoki WadaDepartment of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.
Eiichi MoriiDepartment of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Kiyoshi TakedaWPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Yusuke OjiDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Haruo SugiyamaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Junichi TakagiLaboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
The University of Osaka · JPFuchu Hospital · JPJapan Agency for Medical Research and Development · JPJichi Medical University · JPProtein Research Foundation · JPKyushu University · JPNagoya University · JPOsaka City General Hospital · JPOsaka City University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-specific cell-surface antigens are ideal targets for monoclonal antibody (mAb)-based immunotherapy but are likely to have previously been identified in transcriptome or proteome analyses. Here, we show that the active conformer of an integrin can serve as a specific therapeutic target for multiple myeloma (MM). We screened >10,000 anti-MM mAb clones and identified MMG49 as an MM-specific mAb specifically recognizing a subset of integrin β
Indexed as
AnimalsCell Line, TumorFemaleHEK293 CellsHumansImmunotherapy, AdoptiveIntegrin beta ChainsK562 CellsMiceMice, Inbred NODMice, SCIDMice, TransgenicMultiple MyelomaProtein ConformationReceptors, Antigen, T-CellRecombinant Fusion Proteinsintegrin beta7Integrin beta ChainsReceptors, Antigen, T-CellRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03778346ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.